Home » Reports » USA Broker Ratings » Tokai Pharmaceuticals Inc 243.3% Potential Upside Indicated by Oppenheimer

Tokai Pharmaceuticals Inc 243.3% Potential Upside Indicated by Oppenheimer

Tokai Pharmaceuticals Inc using SYMBOL code NASDAQ:TKAI has had its stock rating noted as ‘Coverage Initiated’ with the recommendation being set at ‘OUTPERFORM’ this morning by analysts at Oppenheimer. Tokai Pharmaceuticals Inc are listed in the Health Care sector within NASDAQ. Oppenheimer have set a target price of 38 USD on its stock. This is indicating the analyst believes there is a potential upside of 243.3% from the opening price of 11.07 USD. Tokai Pharmaceuticals Inc NASDAQ:TKAI has a 50 day moving average of 12.53 USD and the 200 Day Moving Average price is recorded at 14.36 USD. The 1 year high stock price is 30 USD while the 52 week low for the share price is 9.67 USD.

 

Tokai Pharmaceuticals Inc NASDAQ:TKAI is a biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s drug candidate, Galeterone, is a multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer that disrupts androgen receptor signaling through three mechanisms of action. Galeterone acts by disrupting the androgen receptor signaling pathway, which is a pathway that drives prostate cancer growth. The Company has a drug discovery program, ARDA (Androgen Receptor Modulation Optimized for Response). ARDA is focused on the identification and evaluation of compounds with potent androgen receptor degradation activity targeted to patients with androgen receptor signaling diseases, including prostate cancer.

Join us on our new LinkedIn page

Follow us on LinkedIn